Thrombotic and hemorrhagic complications in children and young adult recipients of Hematopoietic Stem Cell Transplant (HSCT)
| Autor: | Kent R. Bailey, Shakila P. Khan, Rajiv K. Pruthi, Aneel A. Ashrani, Dominder Kaur, Vilmarie Rodriguez |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Myeloid Transplantation Conditioning Adolescent Hemorrhage 030204 cardiovascular system & hematology 03 medical and health sciences Young Adult 0302 clinical medicine medicine Humans Platelet Young adult Risk factor Child Retrospective Studies business.industry Incidence (epidemiology) Medical record Hematopoietic Stem Cell Transplantation Infant Newborn Hematopoietic stem cell Infant Thrombosis Hematology medicine.disease surgical procedures operative medicine.anatomical_structure 030220 oncology & carcinogenesis Child Preschool Female business |
| Zdroj: | Thrombosis research. 167 |
| ISSN: | 1879-2472 |
| Popis: | Background Overall incidence of hemostatic complications in pediatric recipients of Hematopoietic Stem Cell Transplant (HSCT) is scarcely studied. This retrospective review explored the incidence and underlying risk factors of bleeding and thrombotic complications in children. Procedure Clinical characteristics, hemorrhagic events (HE), thrombotic events (TE) and follow up data were abstracted from medical records on patients aged Results From start of conditioning until last follow up, 238 pediatric patients were reviewed during this study. There were 16 symptomatic thrombotic complications in 15 patients, along with 13 major bleeding events. Incidence of HE or TE was higher in allogeneic HSCT compared to autologous HSCT (p = 0.02). Severe thrombocytopenia could not be identified as a major contributor to bleeding. All patients with HE had platelets between 20,000–50,000 × 109/L, except one patient, who had platelets Conclusions Allogeneic pediatric HSCT patients had higher overall risk of hemorrhagic or thrombotic complications compared to autologous recipients in this study. HSCT for myeloid malignancies was a risk factor for higher complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect